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CORRECTION
Correction: Tumour-infiltrating CD8+ lymphocytes and
colorectal cancer recurrence by tumour and nodal stage
Mark A. Glaire1, Enric Domingo1,2, Anita Sveen3, Jarle Bruun3, Arild Nesbakken4,5, George Nicholson6, Marco Novelli7, Kay Lawson7,
Dahmane Oukrif7, Wanja Kildal8, Havard E. Danielsen8,9,10, Rachel Kerr11, David Kerr10, Ian Tomlinson12, Ragnhild A. Lothe3,5 and
David N. Church1,11,13
British Journal of Cancer (2019) 121:807; https://doi.org/10.1038/s41416-019-0590-7
Correction to: British Journal of Cancer (2019) 121, 474–482;
https://doi.org/10.1038/s41416-019-0540-4, published online 7
August 2019.
Since the publication of this paper, the authors noticed that the
funding information for E.D. was not included. The correct funding
information is now shown in the Funding section below.
Funding: Funding for this study was provided by: Cancer
Research UK (C6199/A10417 and C399/A2291), the European
Union Seventh Framework Programme (FP7/207- 2013) grant
258236 collaborative project SYSCOL, European Research Council
project EVOCAN, the Oxford Cancer Centre, the Oxford NIHR
Comprehensive Biomedical Research Centre (BRC), and core
funding to the Wellcome Trust Centre for Human Genetics from
the Wellcome Trust (090532/Z/09/Z). M.G. is funded by a
Wellcome Trust Clinical Training Fellowship. E.D. is supported by
the S:CORT consortium which is funded by a grant from the
Medical Research Council and Cancer Research UK. D.N.C. is
funded by a Health Foundation/Academy of Medical Sciences
Clinician Scientist Fellowship. A.S. is funded by a Norwegian
Cancer Society Scientist Fellowship (no. 6824048-2016). R.A.L. is
supported by the Research Council of Norway (no. 250993) and
the Norwegian Cancer Society (no. 182759-2016). M.N. and D.O.
were supported by Cancer Research UK and the National Institute
for Health Research through the UCL Experimental Cancer
Medicine Centre (to D.O.) and UCL Hospitals Biomedical Research
Centre (to M.N.). The views expressed are those of the authors and
not necessarily those of the NHS, the NIHR, the Department of
Health or the Wellcome Trust. The costs of open access publishing
were funded by The Wellcome Trust (090532/Z/09/Z). The study
funders had no role in the design, analysis, interpretation, or
manuscript preparation for this biomarker study. D.N.C. had full
access to all study data and had final responsibility for submission
of this report.
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